Major bleeding in cirrhotic patients was associated with poor outcome.
Fibrinogen, PLT and aPTT were identified as useful tools for prediction of major bleeding in cirrhosis.
Unfractionated heparin has comparable major bleeding in renal impairment compared with unadjusted enoxaparin.
However, the high risk of major bleeding (in 4%-14% of treated patients with thrombolysis) limits their use [4].
Major bleeding in acute coronary syndromes (ACS) is associated with an increased risk of subsequent mortality and recurrent ischemic events.
Fibrinogen level < 60 mg/dl, PLT < 30 G/l and aPTT > 100 s were identified as highly specific thresholds for prediction of major bleeding in cirrhosis.
Fibrinogen (AUROC 0.749, p < 0.001), PLT (AUROC 0.651, p < 0.01) and aPTT (AUROC 0.640, p < 0.01) on admission were associated with major bleeding in cirrhotic ICU patients.
This review aims to examine the relation between baseline anemia and mortality, major adverse cardiovascular events (MACE), and major bleeding in patients undergoing PCI.
A recent study of patients with cirrhosis demonstrated that abnormal coagulation parameters, especially fibrinogen and platelet counts, predict new onset of major bleeding in patients with cirrhosis at the ICU [33].
Several studies have demonstrated an association between body mass index (BMI) and warfarin therapeutic dose, but none evaluated the association of BMI with the clinically important outcome of major bleeding in a community setting.
Edoxaban a non vitamin K antagonist oral anticoagulant (NOAC)— 60-mg and 30-mg once-daily dose regimens are noninferior versus well-managed warfarin for the prevention of stroke or systemic embolic events (SEE) with less major bleeding in patients with nonvalvular atrial fibrillation (NVAF).
